Conferences
Genoskin to attend ESDR 2017
GENOSKIN TO ATTEND 47TH ANNUAL ESDR MEETING 2017 Here at Genoskin, we’re pleased to announce our presence at the 47th Annual Meeting of the European Society for Dermatological Research (ESDR). The meeting will take place in Salzburg, Austria from September 27th to 30th, 2017. The ESDR aims to promote research in dermatology and skin biology and open up the dialogue between
Boston-Paris Biotechnology Summit
Genoskin to attend Boston-Paris Biotechnology Summit In order to better serve our American customers, Genoskin plans to set up a production unit in Boston in 2018. Our project has recently been selected by the NETVA program, which helps companies prepare for this strategic move. In May, we will attend the Boston-Paris Biotechnology Summit, an independent conference supported by a panel of biotech professionals from both sides of the
Genoskin invited to MEDEF meeting on how CEOs can drive change
Every year, the MEDEF, France’s largest entrepreneurial organisation, sets up local conferences in an attempt to bring companies together under a predefined theme. This year, Genoskin was invited to the 7th Edition of the Entrepreneurial Event (Grande Tribune des Entrepreneurs) to contribute to the discussion on the role of CEOs in driving change. The widely attended conference was headed by Pierre Gataz, the MEDEF’s president (see
Genoskin is a winner of the 7th edition of the NETVA contest: See you soon in Boston !
The NETVA (New Technology Venture Accelerator) program consists in a preparation and exposure to high-tech US markets for young innovative French companies. It is run by the Office for Science & Technology of the Embassy of France in the United States in three locations: Boston, San Francisco and Washington, DC. Each year, 15 French startups are selected though a national competition
Genoskin presents new skin cancer model at Meet2Win
Genoskin launches new OncoSkin® skin cancer model at Meet2Win Genoskin has developed a new skin cancer model for the in vitro study of melanoma. Patients who suffer from this highly dangerous type of skin cancer currently have limited therapeutic options when the cancer reaches metastasis. The OncoSkin® skin cancer model now enables in vitro studies on live melanoma spheroids implanted
Genoskin attends 2014 meeting European Society for Dermatological Research
Genoskin develops and markets innovative testing tools to study the effects of pharmaceutical, cosmetic and chemical products on real, live ex vivo human skin.
